Dividend compounder review

HEMO

Hemogenyx Pharmaceuticals Plc · LSE · GB

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score23.00/100
Confidence72.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 8.5 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 6.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 3.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 5.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income£-9.8M
Free Cash Flow£-3.5M
FCF Covers DividendUnknown
Debt / Equity1.75
P/E-
Revenue Growth 5Y-
Net Margin0.0%
ROE-9.8%
Price vs Trend4.7%
3Y Return14.7%
5Y Return-12.4%
CurrencyGBP
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Dividend diary

Activity record

HEMO dividend review warning Warning · Warning

Free cash flow is negative.